Achaogen: Top 5 Biotech VC Deals, H1 2010

Company: Achaogen
Based: San Francisco, CA
Amount: $56M

Investors: Frazier Healthcare Ventures, Alta Partners, 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures, the Wellcome Trust

Scoop: Achaogen is set on reviving a class of antibiotics so old that no company has worked with them in 25 years. Using new chemistry on the aminoglycosides class, Achaogen has developed a next-gen approach dubbed neoglycosides. Achaogen's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase I clinical testing and is now headed for Phase II trials. The drug is being explored as a treatment for multi-drug resistant (MDR) Gram-negative bacteria and MRSA.

Related Articles:
Achaogen - 2009 Fierce 15
Achaogen CEO Kevin Judice
Flush with cash, Achaogen continues antibiotic work
Achaogen raises $56M for antibiotic work